10125-ANGI-1 Comparative analyses of Annexin A2 expression and prognosis during bevacizumab therapy in glioblastoma between effectiveness and refractoriness

Neurooncol Adv · 2025 · PMC12706327

Europe PMC

hedged sentence

0.1037

closest p · 2.1× alpha

0.1037

boldest claim

The sentences

showed a trendp = 0.1037not close (p > 0.1)

T1Gd good responders showed a trend toward longer PFS (p = 0.1037), while T2/FLAIR poor responders also showed a similar trend (p = 0.0688).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.